Pathfinder 2 Clinical Trials

Under the leadership of our oncology providers and in partnership with GRAIL, Inc., Woodlands Medical Specialists participated in the PATHFINDER 2 Clinical Trial, advancing the use of Multi-Cancer Early Detection (MCED) testing.

This innovative blood-based test analyzes cell-free DNA (cfDNA) to detect potential cancer signals and identify their cancer signal origin (CSO), guiding diagnostic evaluation and improving opportunities for early intervention.

Through our involvement in this important research, Woodlands Medical Specialists has contributed to the growing body of evidence supporting FDA review of this early detection technology—helping to shape the future of cancer screening and precision medicine for patients across the United States